Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cassava Sciences, Inc. - Common Stock (NQ:SAVA)

2.290 +0.210 (+10.10%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,103,914
Open 2.110
Bid (Size) 2.260 (10)
Ask (Size) 2.300 (53)
Prev. Close 2.080
Today's Range 2.100 - 2.360
52wk Range 1.150 - 33.98
Shares Outstanding 41,969,994
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Cassava Sciences to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
From Cassava Sciences, Inc.
Via GlobeNewswire
Cassava Sciences Posts Q2 Loss on Pivot
Via The Motley Fool
Topics Intellectual Property

Performance

YTD
-16.7%
-16.7%
1 Month
+0.9%
+0.9%
3 Month
+10.6%
+10.6%
6 Month
-15.8%
-15.8%
1 Year
-92.7%
-92.7%

More News

Read More
Cassava Reports Q2 2025 Financials Results and Provides Business Update
From Cassava Sciences, Inc.
Via GlobeNewswire
Cassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer
From Cassava Sciences, Inc.
Via GlobeNewswire
Cassava Sciences Reports Positive Preclinical Study Evaluating Simufilam for TSC-Related Epilepsy
From Cassava Sciences, Inc.
Via GlobeNewswire
Cassava Presents Promising Preclinical Simufilam Data at TSC Alliance Meeting
From Cassava Sciences, Inc.
Via GlobeNewswire
Cassava Reports Q1 2025 Financials Results, Provides Business Update
From Cassava Sciences, Inc.
Via GlobeNewswire
Cassava Appoints Angélique Bordey, PhD, to Enhance Preclinical Program in TSC
From Cassava Sciences, Inc.
Via GlobeNewswire
Cassava Announces Retirement of Chief Medical Officer, Dr. Jim Kupiec, and Appointment of Dr. Jack Moore as Senior Vice President, Clinical Development
From Cassava Sciences, Inc.
Via GlobeNewswire
Top movers analysis one hour before the close of the markets on 2025-03-25: top gainers and losers in today's session.
Via Chartmill
Cassava Sciences Stock Drops Over 30% After Alzheimer’s Drug Fails Study – But Retail Remains Hopeful
Via Stocktwits
Which stocks are experiencing notable movement on Tuesday?
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Cassava Sciences Discontinues Developing Simufilam For Alzheimer's After Another Phase 3 Trial Flop
Via Benzinga
Which stocks are moving before the opening bell on Tuesday?
Via Chartmill
Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data
From Cassava Sciences, Inc.
Via GlobeNewswire
Tesla Rebounds While Tariffs Weigh On Manufacturing: What's Driving Markets Monday?
Via Benzinga
Cassava Sciences Reports 2024 Financial Results and Provides Business Update
From Cassava Sciences, Inc.
Via GlobeNewswire
Cassava Sciences Licenses Simufilam Method of Treatment Patent
From Cassava Sciences, Inc.
Via GlobeNewswire
Final SAVA Deadline Reminder: February 10, 2025 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP
Via NewMediaWire
Topics Lawsuit
Final SAVA Deadline Reminder: February 10, 2025 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP
Via TheNewswire.com
Topics Lawsuit
SAVA Deadline in 1 Day: Kessler Topaz Meltzer & Check, LLP Reminds Cassava Sciences, Inc. (SAVA) Investors of Filing Deadline in Class Action Lawsuit
Via NewMediaWire
Topics Lawsuit
SAVA Deadline in 1 Day: Kessler Topaz Meltzer & Check, LLP Reminds Cassava Sciences, Inc. (SAVA) Investors of Filing Deadline in Class Action Lawsuit
Via TheNewswire.com
Topics Lawsuit
CASSAVA SCIENCES 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Cassava Sciences, Inc. - SAVA
From Kahn Swick & Foti, LLC
Via Business Wire
SAVA Deadline in 3 Days: Kessler Topaz Meltzer & Check, LLP Reminds Cassava Sciences, Inc. (SAVA) Investors of Filing Deadline in Class Action Lawsuit
Via NewMediaWire
Topics Lawsuit

Frequently Asked Questions

Is Cassava Sciences, Inc. - Common Stock publicly traded?
Yes, Cassava Sciences, Inc. - Common Stock is publicly traded.
What exchange does Cassava Sciences, Inc. - Common Stock trade on?
Cassava Sciences, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Cassava Sciences, Inc. - Common Stock?
The ticker symbol for Cassava Sciences, Inc. - Common Stock is SAVA on the Nasdaq Stock Market
What is the current price of Cassava Sciences, Inc. - Common Stock?
The current price of Cassava Sciences, Inc. - Common Stock is 2.290
When was Cassava Sciences, Inc. - Common Stock last traded?
The last trade of Cassava Sciences, Inc. - Common Stock was at 09/18/25 04:00 PM ET
What is the market capitalization of Cassava Sciences, Inc. - Common Stock?
The market capitalization of Cassava Sciences, Inc. - Common Stock is 96.11M
How many shares of Cassava Sciences, Inc. - Common Stock are outstanding?
Cassava Sciences, Inc. - Common Stock has 96M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.